Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Mudrick Capital Acquisition Corporation Announces Pricing of $200,000,000 Initial Public Offering
-
Chardan Capital Markets Starts Kamada Ltd. (KMDA) at Buy
-
Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option
-
Chardan Capital Markets Starts Vocera Communications (VCRA) at Buy, Sees Good Execution Driving Multiple Expansion
-
Vuzix Announces Closing of Above Market $30,000,000 Offering
-
Solid Biosciences (SLDB) IPO Opens Up 59%
-
Solid Biosciences Inc. (SLDB) Prices 7.81M Share IPO Offering at $16/Sh
-
Solid Biosciences Announces Pricing of Initial Public Offering
-
Vuzix Corp. (VUZI) to Sell 3M Shares at $10 with Warrants
-
Vuzix Announces $30,000,000 Above Market Intra-Day Registered Direct Offering
-
Medicines Co. (MDCO): Top Pick for 2018 - Chardan
-
Sunworks (SUNW): Solar Decision Removes Uncertainty and is Better than Feared - Chardan
-
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
-
Iovanace Biotherapeutics (IOVA) PT Raised to $30 at Chardan Capital Markets, Top Pick for 2018
-
Chardan Capital Markets Starts Arcturus Therapeutics (ARCT) at Buy, Could Become Significant Competitor In RNA Molecular Therapies
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $175 at Chardan Capital Markets
-
Arrowhead Pharmaceuticals Corp (ARWR) Prices 10M Common Stock Offering at $5.25/Share
-
Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
-
PlacementTracker Publishes 2017 PIPE and Private Placement Markets League Tables
-
GigCapital, Inc. Announces the Separate Trading of its Common Stock, Rights and Warrants, Commencing January 17, 2018
-
GigCapital, Inc. Announces Closing of Over-Allotment Option in Connection With Its Initial Public Offering of Common Stock
-
Chardan Capital Markets Upgrades Axovant Sciences (AXON) to Neutral Citing Less Scope for Underperformance
-
UPDATE: CaesarStone Sdot-Yam (CSTE) Upgraded to Buy at Chardan Citing Valuation
-
Chardan Capital Markets Starts Nightstar Therapeutics (NITE) at Buy
-
Chardan Capital Markets Downgrades The KEYW Holding Corporation (KEYW) to Neutral Citing Valuation
-
Solid Biosciences Files $100M NASDAQ IPO; Plans to List Under Ticker 'SLDB'
-
Vuzix Announces Closing of US$12.5 Million Offering
-
Vuzix Corp. (VUZI) Announces $12.5M Registered Direct Offering of Common Stock, Warrants
-
Vuzix Announces $12,500,000 Registered Direct Offering
-
VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
-
GigCapital, Inc. Announces Closing of Public Offering of Common Stock
-
Spark Therapeutics (ONCE) PT Lowered to $60 at Chardan Capital Markets
-
VistaGen Therapeutics (VTGN) Prices 10M Offering of Common Stock and Warrants
-
VistaGen Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
-
GigCapital Inc. (GIG.U) Prices 12.5M Share IPO at $10/Sh
-
GigCapital, Inc. Announces Pricing of $125,000,000 Initial Public Offering
-
Tabula Rasa HealthCare Announces Pricing of Sale of Shares of Common Stock
-
Esperion Therapeutics (ESPR) PT Raised to $75 at Chardan Capital Markets; Positive Bias
-
Tabula Rasa HealthCare (TRHC) Announces 3M Share Offering
-
Tabula Rasa HealthCare Announces Proposed Offering of Common Stock
-
Chardan Capital Markets Downgrades Ituran Location & Control (ITRN) to Neutral
-
Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Alnylam Pharma (ALNY) Prices 5.6M Share Common Offering at $125/Sh
-
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
-
Vuzix Corp. (VUZI): Entering 2018 with Significant Momentum - Chardan
-
Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy
-
Jensyn Acquisition Corp (JSYN) to Merge with BAE Energy Management
-
Jensyn Acquisition Corp. Announces Agreement for Business Combination with BAE Energy Management, LLC
-
Regenxbio Inc. (RGNX) PT Raised to $85 at Chardan Capital Markets
-
CaesarStone Sdot-Yam (CSTE) PT Lowered to $32 at Chardan Capital Markets

